Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight ... which are both based on the same basic ingredient, semaglutide. At the peak, the company’s market capitalization ...

Novo Nordisk's semaglutide starts global phase 3 trials. In December 2016, it files semaglutide for regulatory approval in the U.S. and the EU, based on the results from the six trials.

Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S ... which are both based on the same basic ingredient, semaglutide. Rapidly expanding school voucher programs pinch ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S ... which are both based on the same basic ingredient, semaglutide. At the peak, the company’s market capitalization ...

Novo Nordisk said Friday that CEO Lars Fruergaard Jørgensen is stepping down as the Wegovy maker seeks to revive its ailing fortunes amid increasing competition. The Danish pharmaceutical giant ...